An alternative cancer treatment: Extracorporal Modified Immune Therapy (EMIT)
Moreover, other problems emerge: Those who do not belong to academic circles will neither be perceived nor be supported by the public corporation and/or professional associations in general. By the way, I would not object a verification of the method by an independent clinical study.
Dr. med Sadik Öz (SOEZMED):
- STUDY (1979 − 1985)
Human Medicine at the University of Regensburg ( Physikum ) or University Erlangen-Nuremberg
- MEDICAL EDUCATION (1988 − 1995)
in the Med . Klinik III Uni – Erlangen Med . Clinic IV , Klinikum Nürnberg and Med . Clinic V , Nuremberg Hospital
- CANCER RESEARCH (SINCE 1981)
September 1981 – September 1985 − Doctoral thesis
September 1985 – August 1986 − Assistant Professor at the Department of Immunology and Rheumatology,
Med . Klinik III Uni – Erlangen
September 1986 – June 1987 − Researcher at the Sloan Kettering Cancer Center, New York, USA
July 1987 – January 1988 − MHH Hannover Pediatric Oncology
February 1988 – December 1991 − Med. Klinik III Uni-Erlangen Haematological malignancies
July 1991 – August 1995 − Med. Klinik V, Klinikum Nürnberg Haematological malignancies
September 1995 to date − Independent researcher
- DOCTOR’S SURGERY SINCE 1995
Dr. med. Sadık Öz • Feuerweg 21 • 90443 Nürnberg • +49 911 92919620
Tel. + 49 9123 14957
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release An alternative cancer treatment: Extracorporal Modified Immune Therapy (EMIT) here
News-ID: 326086 • Views: 785
More Releases from PBirkel
The new concept: EMIT - CANCER IS CURABLE
The new concept: EMIT - CANCER IS CURABLE In the course of approximately 30 years in cancer research (see curriculum vitae) I have been trying to work out a new strategy to overcome the problems mentioned above. Based on my observations I assume that the mode of therapy should comprise not only the destruction of the tumor cell, but should focus on its “conversion”, “re-education” into normal functioning body cells. I
Extracorporal Modified Immune Therapy (EMIT)
A tumor patient usually does not die from a benign tumor, but from a malignant tumor that maintains an uninhibited proliferation, which in turn interferes fatally with the vital functions of other organs. Apart from surgical procedures at an early stage, conventional cancer therapy is based on the philosophy that cancer cells should be destroyed with various destructive methods such as chemotherapy, radiation therapy, TKI, monoclonal antibodies, etc. All immunological research
May renal cell carcinoma be cured by EMIT?
A 50 year-old male patient asked for help: A left-sided renal mass had been detected in an abdominal CT-scan performed due to a preceding gross hematuria. Abdominal CT-scan: Inhomogeneous tumor with a diameter of approximately 9.5 cm in the left kidney. Additionally, several enlarged aortic lymph nodes (about 8 mm in size) as well as a tumor in the left adrenal with a diameter of 10 mm. Pathological evaluation Macroscopy: Left kidney,